Diabetic Kidney Disease Market Synopsis:
\nDiabetic Kidney Disease Market Size Was Valued at USD 2.7 Billion in 2023, and is Projected to Reach USD 4.4 Billion by 2032, Growing at a CAGR of 5.4% From 2024-2032.
\nDiabetic Kidney Disease (DKD), sometimes referred to as diabetic nephropathy, is a chronic kidney disease triggered by injuries to the kidneys resulting from long-term diabetes effects mostly in T1DM and T2DM patients. Another is described by the progressive worsening of the kidney functionality hinding the failure of the organ if not treated. This condition is caused by high blood sugar levels that affect blood vessels in the kidneys and reduce their capacity for clearing waste products. This is one of the main conditions leading to ESRD and patients develops dialysis or kidney transplantation.
\nDemand for Diabetic Kidney Disease treatment has been on the rise in recent years because of the steady upward trend of diabetes cases globally. Especially technology for diagnosis kit and immunosuppressive therapy, increasing incidences of both Type 1 and 2 diabetes which make diabetic patients more prone to chronic kidney diseases will foster the growth of this market. The International Diabetes Federation gave a figure of 537 million adults living with diabetes in 2021, and further millions are expected to develop the condition in the next few years. Admission rates for diabetic complications like diabetic kidney disease are increasing due to increasing cases of diabetes and people living with diabetes are aging.
\nAnother factor that cannot be overlooked when reviewing the sources of the DKD market growth is the increasing knowledge of complication diagnosing and its treatment. Nuevoas diagnosticos, medicamentos y terapias emporque DKD enhanced the quality of life for the diabetic patients including AEC inhibitors, ARBs. Governments and other healthcare organizations are also dedicating a greater amount of spending on awareness campaigns regarding early diagnosis and treatment, which will provide added fuel to the fire in terms of market growth. However, factors such as the expensive cost of treatment and poor access to quality health service in the developing economies may limit the growth of the market in some markets.<\/p>\n
Diabetic Kidney Disease Market Trend Analysis:
\nIncreasing Focus on Novel Therapies<\/p>\n
A major trend that is revolutionizing the Diabetic Kidney Disease market pool is the use of staking on new therapeutic platform: precision medicine and biologics. The currently the medications such as ACE inhibitors and ARBs are important for treating DKD because of the newer drug class including SGLT2 inhibitors and non-steroidal MRAs. Clinical trials as well as research projects concerning the usefulness of these innovative therapies indicate that they slow the progression of DKD and decrease cardiovascular complications. Also, new approaches to a patient\u2019s treatment tailored to his or her genotype are being developed, enhancing patient-oriented therapy and the latter\u2019s results. The research pipeline in this area is quite deep, and many drug makers are starting to devote large sums to discovering new treatments.
\nExpanding Opportunities in Early Detection and Prevention<\/p>\n
One of the major opportunities of the Diabetic Kidney Disease market is that there is potential to identify renal hazards at early stages among diabetic patients. Thus, there can be observed more and more attention to cost-efficient models of primary prevention and to identification of populations that are most likely to deteriorate their health in the nearest future. Point of care diagnostics, biomarker based tests and wearables are being invented to measure kidney function and blood glucose more effectively. As with most diseases, early identification of kidney dysfunction can help healthcare practitioners prevent or slow the progression of severe kidney injury. Moreover, the adoption of remote patient monitoring apps such as telemedicine enables market players to address the DKD patient population in the currently underpenetrated or rural markets that present a significant and growing opportunity.
\nDiabetic Kidney Disease Market Segment Analysis:
\nDiabetic Kidney Disease Market Segmented on the basis of type, Treatment and Distribution Channel.
\nBy Type, Type 1 Diabetes segment is expected to dominate the market during the forecast period<\/p>\n
From the type perspective, the Type 1 Diabetes segment would hold the major share in the Diabetic Kidney Disease market throughout the forecast period. Hypertension can still be associated with either type of diabetes but the patients with type 1 diabetes have higher chances of developing the disease because they have exposed their kidneys for a longer period. Diabetic complications are bound to surface at an earlier stage in Type 1 diabetes since the disease usually develops in early childhood. Chronic exposure to high blood sugar levels manifests in severe and irreversible long term effects in the kidneys. Therefore, we see a more demand for preventive therapeutic modes as well as the early stage therapies for the treatment of DKD among the type 1 diabetic patient population driving this segment.
\nBy Treatment, Angiotensin Receptor Blockers (ARBs) segment expected to held the largest share <\/p>\n
As for the treatment segment, the Angiotensin Receptor Blockers (ARBs) would dominate the Diabetic Kidney Disease market in the forecast period. ARBs are usually prescribed in the therapy of hypertension and lowering proteinuria in patients with DKD. Since angiotensin II constrains blood vessels, ARBs prevent its impact resulting to reduced blood pressure and preserving the kidney in the process. Nine were usually recommended for use in patients with DKD to halt its progression rates. This wider prescription among diabetic patients coupled with effectiveness of ARBs and low incidence of side effects than other therapies enhance their market demand. Also, growing the prescriptions of combination therapies which comprise of an ARB are also enhancing the growth of this segment.
\nDiabetic Kidney Disease Market Regional Insights:
\nNorth America is Expected to Dominate the Market Over the Forecast period <\/p>\n
According to the report, in 2023 North America has witnessed the highest market share in the Diabetic Kidney Disease market. High incidence of diabetes, well-developed healthcare infrastructure, accessibility of advanced treatment for DKD are some of the factors which has provide dominance to this region. Especially, the U.S. has a large number of diabetes patients, 34 million people were diagnosed with the disease. Moreover, ongoing pharmaceutical innovation in the key pharmaceutical companies developing novel treatments for DKD also supports this industry and as per this leadership status will continue. The North America region is projected to account for approximately 40% of the market share for the DKD market due to the following factors: The ongoing improvement and research progress of drugs integral to the treatment of DKD general reimbursement policies in North America, and the central concentration on the early diagnosis of the DKD.
\nActive Key Players in the Diabetic Kidney Disease Market:<\/p>\n
AbbVie Inc. (USA)<\/p>\n
AstraZeneca PLC (UK)<\/p>\n
Bayer AG (Germany)<\/p>\n
Boehringer Ingelheim (Germany)<\/p>\n
Bristol-Myers Squibb (USA)<\/p>\n
Eli Lilly and Company (USA)<\/p>\n
GlaxoSmithKline plc (UK)<\/p>\n
Johnson & Johnson (USA)<\/p>\n
Merck & Co., Inc. (USA)<\/p>\n
Novartis AG (Switzerland)<\/p>\n
Novo Nordisk A\/S (Denmark)<\/p>\n
Pfizer Inc. (USA)<\/p>\n
Sanofi (France)<\/p>\n
Takeda Pharmaceutical Company Ltd. (Japan)<\/p>\n
Teva Pharmaceutical Industries Ltd. (Israel)<\/p>\n
Other Active Players<\/p>\n","protected":false},"excerpt":{"rendered":"
Diabetic Kidney Disease (DKD), sometimes referred to as diabetic nephropathy, is a chronic kidney disease triggered by injuries to the kidneys resulting from long-term diabetes effects mostly in T1DM and T2DM patients. Another is described by the progressive worsening of the kidney functionality hinding the failure of the organ if not treated. This condition is caused by high blood sugar levels that affect blood vessels in the kidneys and reduce their capacity for clearing waste products. This is one of the main conditions leading to ESRD and patients develops dialysis or kidney transplantation.<\/p>\n","protected":false},"featured_media":24042,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-26851","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n